Antiphospholipid Syndrome – Causes, Symptoms & Treatment
Antiphospholipid syndrome (APS) is an autoimmune disorder causing abnormal blood clotting and pregnancy complications due to specific antibodies targeting the body's own proteins.
Things worth knowing about "Antiphospholipid syndrome"
Antiphospholipid syndrome (APS) is an autoimmune disorder causing abnormal blood clotting and pregnancy complications due to specific antibodies targeting the body's own proteins.
What is Antiphospholipid Syndrome?
Antiphospholipid syndrome (APS) is an acquired autoimmune disorder in which the immune system mistakenly produces antibodies against certain phospholipid-binding proteins in the blood. These antibodies increase the risk of abnormal blood clot formation in arteries and veins, as well as pregnancy-related complications such as recurrent miscarriages and preeclampsia. APS can occur as a standalone condition (primary APS) or in association with other autoimmune diseases, most commonly systemic lupus erythematosus (SLE) (secondary APS).
Causes
The exact cause of APS is not yet fully understood. It involves a misdirected immune response in which the body produces antibodies against its own phospholipid-associated proteins. The most clinically relevant antibodies include:
- Lupus anticoagulant
- Anticardiolipin antibodies (aCL)
- Anti-beta-2 glycoprotein I antibodies (ß2GPI)
Known risk and triggering factors include:
- Genetic predisposition
- Other autoimmune diseases (e.g., SLE, rheumatoid arthritis)
- Certain infections (e.g., HIV, hepatitis C, Lyme disease)
- Certain medications (e.g., hydralazine, phenytoin)
Symptoms
Symptoms of APS are mainly caused by the increased tendency for blood clot formation. Common manifestations include:
- Deep vein thrombosis (DVT): Blood clots in the deep veins, most often in the legs
- Pulmonary embolism: A blood clot blocking a pulmonary blood vessel
- Stroke or transient ischemic attacks (TIA)
- Heart attack in younger patients without classical cardiovascular risk factors
- Pregnancy complications: Recurrent miscarriages, stillbirth, preterm birth, and preeclampsia
- Livedo reticularis: A net-like, bluish-purple discoloration of the skin
- Thrombocytopenia (low platelet count)
In rare and severe cases, catastrophic APS (CAPS) can develop, characterized by rapid multiorgan failure due to widespread microvascular thrombosis.
Diagnosis
The diagnosis of APS is based on a combination of clinical features and laboratory findings. According to the internationally recognized Sapporo criteria (revised in 2006), both a clinical criterion and a laboratory criterion must be fulfilled:
Clinical Criteria
- At least one documented thrombotic event in an artery, vein, or small vessel
- One or more pregnancy losses after the 10th week of gestation, three or more consecutive early miscarriages before the 10th week, or a premature birth before the 34th week due to preeclampsia or placental insufficiency
Laboratory Criteria
- Detection of lupus anticoagulant, anticardiolipin antibodies, or anti-ß2GPI antibodies at medium to high levels
- The finding must be confirmed on two separate occasions at least 12 weeks apart
Additional tests such as a full blood count, coagulation studies, and imaging procedures (e.g., ultrasound, MRI) may be used to assess complications.
Treatment
The primary goal of treatment is to prevent further thrombotic events and manage existing complications. Therapy is tailored to the individual risk profile of each patient.
Anticoagulation (Blood Thinning)
- Heparin and vitamin K antagonists (e.g., warfarin, phenprocoumon) are the standard treatment after confirmed thrombosis
- The intensity of anticoagulation (target INR) depends on the type and location of the thrombotic event
- Direct oral anticoagulants (DOACs) may be used in certain cases but are generally not recommended as first-line therapy for high-risk APS
Treatment During Pregnancy
- Combination of low-molecular-weight heparin and low-dose aspirin to reduce pregnancy loss
- Close monitoring by specialist physicians throughout pregnancy
Treatment of Catastrophic APS (CAPS)
- Intensive care management
- High-dose anticoagulation, corticosteroids, intravenous immunoglobulins, and plasmapheresis
General Measures
- Avoiding additional risk factors such as smoking, estrogen-containing contraceptives, and prolonged immobility
- Regular follow-up appointments with a specialist
Prognosis
With consistent treatment and regular monitoring, many patients with APS can lead largely normal lives. However, the risk of recurrent thrombosis remains elevated, often requiring long-term or lifelong anticoagulation therapy. Early diagnosis and close medical follow-up are essential for a favorable prognosis.
References
- Miyakis S. et al. – International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis, 2006.
- Devreese K. M. J. et al. – Antiphospholipid antibodies and the antiphospholipid syndrome: Pathogenesis, diagnosis, and treatment. Seminars in Thrombosis and Hemostasis, 2023.
- European League Against Rheumatism (EULAR) – Recommendations for the management of antiphospholipid syndrome in adults, 2019.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryWound healing optimization
Intestinal barrier markers
Ovulation induction
Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Antiphospholipid syndrome